the 1993 National Institutes of Health Revitalization Act, which mandates inclusion of minorities and women in National Institutes of Health-sponsored research (1) . Since its publication, the identification and elimination of racial and sex disparities is a stated goal of the National Institutes of Health and the Institute of Medicine (2) (3) (4) . Despite this mandate, underrepresentation of minorities and women in clinical research remains common in clinical trials of cancer, cardiovascular, and HIV therapies (5) (6) (7) (8) . Similar National Institutes of Health guidelines advocating for the inclusion of elderly patients in medical research do not exist despite the consistently reported underrepresentation of the elderly in cardiovascular and cancer clinical trials (7, 9) .
Racial/ethnic minorities and older patients have a disproportionate burden of critical illness. For example, the incidence of sepsis among black Americans is twice that of white Americans (10, 11) , and once present, minorities are at greater risk of death (11) . The incidence of and mortality from acute lung injury (ALI) is also greater among racial/ethnic minorities compared with whites (12, 13) and steadily increases with age such that patients Ͼ75 yrs of age are at the greatest risk of developing and dying from this disease (14 -17) . Given the rapidly aging population and the increasing proportions of racial/ethnic minorities in America, the societal burden of these diseases is expected to only increase (18) .
Appropriate eligibility and exclusion criteria are essential for the internal validity and safety of efficacy trials. However, inadvertent omission of the elderly, women, and racial/ethnic minorities in critical illness clinical trials may compromise the generalizability of such studies; prevent exploration of necessary subgroup analysis by age, sex, or race/ethnic group; and perpetuate current disparities in equitable access to the latest therapies (19) . To date, no study provides a broad characterization of the participation of older patients, women, and racial/ ethnic minorities in clinical trials in critical care (20) .
We sought to determine whether there were differences in enrollment by age, sex, or race/ethnicity in ALI clinical trials. We also examined the reasons for nonenrollment among screened patients in these. We hypothesized that older patients would be less likely to be enrolled than younger patients; black patients would be less likely to be enrolled than white patients; and women would be less likely to be enrolled than men. Some of the results of this study have been previously reported in the form of an abstract (21, 22) .
MATERIALS AND METHODS
The study was approved by the Institutional Review Board of the University of Washington. Seven local Institutional Review Boards at centers where the parent studies were conducted refused the release of patient data for patients who were not enrolled. All patients from these centers were excluded. Study Sample. We performed a crosssectional analysis of pooled screening logs collected during the three randomized, multicentered clinical trials carried out by the Acute Respiratory Distress Syndrome Network's (ARDSnet). The three included studies were: Ketoconazole and respiratory management in the treatment of ALI and ARDS trial (KARMA) (23); The Assessment of Low tidal Volume and elevated End-expiratory volume to Obviate Lung Injury trial (ALVEOLI) (24) ; and The Fluid and Catheter Treatment Trial (FACTT) (25, 26) . For all studies, patients who were intubated and receiving mechanical ventilation were eligible for enrollment if they met the American-European Consensus Conference definition for ALI (27) . Specific exclusion criteria and further details about the three studies are in Supplemental Table 1 (see Supplemental Digital Content 1, http://links.lww.com/CCM/A140).
Screening Data Quality. There was no standardized ALI screening practice across ARDSnet centers and the approach to screening in each center was not recorded. Within each study center, local investigators determined which intensive care units would be screened, how many days per week screening occurred, and which patients would be written into the screening log. Some centers were given financial compensation for each patient screened, whereas others were not. Although all exclusion criteria for each nonenrolled patient screened during FACTT were collected, investigators only captured one exclusion criterion for patients screened for KARMA and ALVEOLI. When more than one exclusion criterion was present, no guidelines were available to facilitate selection of the criterion for log entry. For our analysis, we excluded patients who were included in screening logs but did not have ALI; patients missing data for age, sex, race/ethnicity; and patients who were not enrolled because they were too young.
Definitions and Measurements. We defined enrollment fraction as the number of patients who were enrolled in a clinical trial divided by the total patients screened for enrollment. Age and sex were coded by investigators at the time of screening for ALI. To determine race/ ethnicity, study personnel examined the patient, reviewed the medical record, and spoke with the family. Patients were classified into six mutually exclusive categories: white, non-Hispanic; black, non-Hispanic; Hispanic; Asian or Pacific Islander; and Native American or Alaskan native; or other. With the exception of PAO 2 /FIO 2 ratio and predisposing ALI risk factor, no other physiology, laboratory, or outcome data were available on nonenrolled patients.
Statistical Analysis. We used chi-square, Fisher's exact, or Student's t test as appropriate for all bivariate comparisons. We used logistic regression to determine the likelihood of enrollment by age, sex, and race/ethnicity stratified by hospital adjusting for other potential confounding variables. Age was categorized by decade (Ͻ36 to 75ϩ years) to allow for a nonlinear relationship in regression. Given the known wide variation in screening practices, patient populations, and other institutional-level factors, we used conditional logistic regression with enrollment as the outcome variable to address confounding by study center after excluding statistical heterogeneity in enrollment by race across sites using the Breslow-Day test of homogeneity (28) . We explored multiplicative interactions among age, sex, race/ethnicity and among these three variables and ARDSnet study and retained interactions significant at the p Ͻ .05 level. We repeated similar analyses to study the relationship between each reason for nonenrollment and age, sex, and race/ethnicity. A separate model was developed for each of the 24 exclusion criteria with each exclusion criterion serving as the outcome. The coefficient for age was scaled to represent the ratio in the odds for the presence of the exclusion criterion for each 10-yr increment in age. All models included age, sex, race/ethnicity, ALI risk factor, study, and study center. We excluded patients coded as "other" race/ethnicity from regression analyses as a result of the difficulty in interpreting the meaning of this group.
To determine the influence of moribund status on the reported odds ratios for enrollment among the older patients, we removed patients who were not enrolled because they were not committed to full support (n ϭ 611) or who had a terminal illness (n ϭ 1507) in a sensitivity analysis.
RESULTS
Pooled screening logs from the three studies at 48 centers identified 23,819 patients of whom 23,419 had ALI. Of these, 2452 (10.5%) enrolled in a study. We excluded 5960 (25%) patients because they were too young or were missing data or Institutional Review Board approval leaving 17,459 patients from 44 centers available for unadjusted analysis ( Fig. 1) .
Patient Characteristics. A total of 1855 (10.6%) of the 17,459 screened patients were enrolled in a clinical trial. On bivariate analysis, enrolled patients were more likely to be younger, female, black or Hispanic, and have pneumonia, sepsis, or aspiration as their predisposing risk factor for ALI compared with nonenrolled patients (Table 1 ). In addition, enrolled patients had lower PAO 2 /FIO 2 ratios compared with nonenrolled patients (130 vs. 158, p Ͻ .001) and were more often cared for in medical versus surgical intensive care units.
Screening Log Characteristics. There was considerable variability in the number of patients screened for enrollment, the enrollment fraction, and racial makeup of screened patients across the 44 study centers ( Table 2 ). The median (interquartile range) volume of screened patients was 154 (34 to 426) and median enrollment fraction was 16% (10% to 33%). The median percent of screened patients who were white was 74% (54% to 83%), whereas the median percent of black patients screened was 14% (3% to 29%). Variability in the age distribution and other racial/ethnic groups across centers was much smaller.
Adjusted Enrollment. For the regression models, we excluded an additional 48 patients from seven centers because enrollment was 100% or 0% for these centers preventing within-center comparisons, leaving 17,411 patients available for regression.
There was no evidence of statistical heterogeneity in enrollment for each race/ethnic group compared with white patients across the study centers (Breslow-Day chi-square test, p Ͼ .16 for all race/ethnicities). There was a statistically significant multiplicative interaction between age and sex in the regression model (p ϭ .03). After adjustment for age, sex, age-sex interaction, ALI risk factor, study, and site, there were no differences in the odds of enrollment for any racial/ethnic group compared with white patients (Table 3) .
Age and sex were both significantly associated with enrollment. In general, men were less likely to be enrolled compared with women and as age increased, patients among both sexes were less likely to be enrolled in an ARDSnet study (Table 3) . Among men and women, each decade beyond 36 yrs of age showed reductions in the odds of enrollment. Men Ͼ75 yrs of age were 41% less likely to be enrolled (odds ratio [OR], 0.59; 95% con-fidence interval [CI], 0.45 to 0.77) and women Ͼ75 yrs of age were 55% less likely to be enrolled (OR, 0.45; 95% CI, 0.32 to 0.62) compared with men Ͻ36 yrs of age.
When patients who were not enrolled either as a result of the presence of a terminal illness or because they were not committed to full support were removed from these models, results were unchanged for all coefficients (results not shown).
Exclusion Criteria. Of the 15,604 patients not enrolled, 91% had one recorded exclusion criterion, 8% had two, and 1% had three or more exclusions. Age and Sex. After adjusting for confounding variables, older patients were less likely to be enrolled as a result of the presence of a comorbid condition ( Fig. 2) . Exclusion criteria present more frequently in older patients included: the presence of an acute myocardial infarction, chronic lung diseases, not committed to full support, presence of a pulmonary artery catheter since ALI onset, and presence of a terminal illness. In contrast, older patients were less likely to be excluded as a result of physician refusal, neuromuscular disease, coenrollment in other studies, patient inability to consent and surrogate not available, acute or chronic liver disease, morbid obesity, burns, and bone marrow or lung transplant. Statistically significant adjusted ORs for the presence of each exclusion for women compared with men are shown in Figure 3 . We identified no consistent patterns.
Race. Black patients (OR, 1.49; 95% CI, 1.24 to 1.79), Hispanic patients (OR, 2.15; 95% CI, 1.65 to 2.79), and American Indian/Alaskan Native patients (OR, 1.82; 95% CI, 1.11 to 2.98), were more likely than white patients to be excluded as a result of patient inability to consent or absence of a surrogate (Fig. 4 ).
DISCUSSION
Using study screening data from Ͼ17,000 patients evaluated for enrollment in three multicentered, randomized trials conducted by the ARDSnet, we determined that there was considerable variability in the number of patients screened for enrollment, the enrollment fraction, and racial/ethnic makeup of screened patients across the study center. Significant differences in enrollment in ALI clinical trials exist across age and sex groups, but not among racial/ethnic groups. Men were enrolled less often than women across all age groups, whereas older men and women were enrolled less often than their younger counterparts. Among excluded patients, all racial/ ethnic minorities were more likely to be excluded as a result of an inability to consent and lack of a surrogate, and black patients were more likely to be excluded as a result of patient or family refusal compared with white patients. The presence of comorbid disease was a more common reason for trial exclusion among older patients.
There is a long history of investigators excluding older patients from clinical trials (9, 29) . Government efforts (30) and the publication of stricter reporting standards for exclusion criteria in clinical trials (31) have modestly reduced the exclusion of older adults from research (9); explicit age limits are now less likely found in contemporary clinical trials (32) . The ARDSnet places no upper limit on age for eligible patients. Yet despite the absence of age exclusions in ARDSnet studies, patients Ͼ75 yrs of age were almost half as likely to be enrolled compared with younger patients. Older patients were underrepresented because they were more likely to have exclusion criteria, which included a lack of commitment to full support or a comorbid condition.
Selecting inclusion and exclusion criteria for clinical studies requires balancing the internal validity of the study and generalizability of its results (19) . By nar- a Excludes all patients identified as "other" race/ethnicity (n ϭ 234) and 48 patients from seven centers with 100% or 0% enrollment; b adjusted for clinical trial, study center, and risk factor for acute lung injury. rowing enrollment criteria, efficacy studies seek to identify a sample of patients who have the greatest likelihood of producing a clinically meaningful and statistically significant benefit from the studied intervention and have the least likelihood of suffering harm (9) . Unfortunately, these studies often fail to address the effectiveness of the treatment in actual practice in which patients with ALI are frequently older and have more comorbidities (16) . These issues are particularly important given the increasing incidence of ALI with age and the aging US population (15, (33) (34) (35) .
The literature documenting sex and racial/ethnic disparities in clinical trial enrollment in other areas of medicine is extensive with little evidence that national efforts to improve diversity in enrollment have been effective (5) (6) (7) . Thus, we were surprised to determine that neither women nor racial/ethnic minorities were underrepresented in ALI clinical trials. In fact, our results indicate that women are more likely to be enrolled than men. One possible explanation for these findings is that the ARDSnet made a concerted effort to include centers serving diverse populations to ensure that women and minorities were adequately represented in its clinical trials. Sexbased differences in enrollment were not attributable to patient or family preferences or physician refusal to enroll, but rather a function of differing prevalence of comorbidities and other exclusion criteria between men and women. Although our best estimates suggest that no racial/ ethnic enrollment differences exist, readers should note that the 95% CIs for the enrollment estimates among minority groups do not exclude the possibility that meaningful differences in enrollment exist.
Although the ARDSnet achieved equivalent enrollment fractions among age, sex, and racial/ethnic groups, it is unclear if enrollment rate is the best measure of "appropriate" enrollment. One arguably better measure of enrollment appropriateness is proportionality-the extent to which the distribution of age, sex, and race/ethnicity in ARDSnet studies reflects the distribution of ALI in the general population (7) . Men and women Ͼ64 yrs old represent approximately 11% and 15% of the population, respectively (18) . Our results indicate that men and women were enrolled in ALI trials at rates of approximately 17% and 16%, respectively, which is considerably lower than would be expected because the incidence of ALI peaks in this age group (16) . Recent population-based data suggest black patients may have twice the incidence of ALI compared with white patients (12) . Given these figures, it is important to note that the proportion of participants identified as black within each ARDSnet study used in our analysis ranged from 14% to 22% (23, 24, 26) , which exceeds the 13% of Americans who are black (18) . This suggests that even when using proportionality as a measure of appropriate enrollment, ARDSnet has succeeded in adequately representing racial/ethnic minorities. Perhaps the ideal measure of proportionality would compare enrollment rates across groups with the population of patients served by each ARDSnet center. We were unable to conduct these analyses because the study center was deidentified in our data. Reason for exclusion by race/ethnicity. For each exclusion criterion, point estimates and 95% confidence intervals for the odds ratio of having the exclusion criterion for each racial/ethnic group are presented. White, non-Hispanic patients who did not enroll serve as the referent category and are not presented. Odds ratios are adjusted for age, sex, primary risk factor for acute lung injury, study, and study center. Exclusion criteria that have a statistically significant association with race/ethnicity (p Ͻ .05) are shown. Missing racial/ethnic categories represent analyses that required collapsing of Asian/Pacific Islander and Native American/Alaskan Native into a single group represented by "collapsed." Criteria marked with a symbol ( †) were available only for the Fluid and Catheter Treatment Trial. PAC, pulmonary artery catheter; ALI, acute lung injury. Despite no differences in overall enrollment fractions, black compared with white patients were more likely to have patient or family refusal as the reason for study exclusion. This may reflect existing mistrust of the research environment held by many black patients (36 -39) , potentially exacerbated by an aversion to technology, an inescapable feature of the intensive care unit (40) . Additional hypotheses for these differences include a lack of research staff diversity potentially undermining trust between patients and staff (37, 41) . Other well-described socioeconomic barriers to participation more commonly found among black patients such as poor access to care (39), a greater perceived economic burden of research (42) , and barriers to communication (39) are potential explanations that require further study in intensive care unit populations. Although important to investigate further, readers should note the absolute difference in rates between white and black patients for this exclusion were small.
We recognize several limitations to our analysis. First, our data derived from the study screening logs collected at each study site. Screening practices and the collection of exclusion criteria were not standardized across centers and only a single exclusion criterion was collected for each individual in two of the three studies. Variability in screening practice may influence the crude estimates of the enrollment fraction. However, these differences should not influence our adjusted enrollment comparisons unless screening occurred in a biased fashion based on age, sex, or race within a given center because our conditional analysis performs all comparisons within a given center. The absence of differential enrollment for black versus white patients who we report could have occurred if black patients were selectively underscreened, but this would have had to occur across all centers. Although it is highly unlikely that all centers actively or inadvertently differentially screened based on age, sex, or race, in the same way, the lack of available information on screening practice prevented exploration of this possibility. Second, race/ethnicity of the patient was determined by the investigator without a protocol that may not accurately represent a patient's true race. Nevertheless, this is the same data reported to the National Institutes of Health for study monitoring purposes and is similar to how race is determined in most studies in the intensive care unit. If present, it is likely that misclassification of race within a center did not differ based on a patient's enrolled status. Third, we excluded Ͼ24% of the screened patient population in sites whose local Institutional Review Boards did not allow release of data for nonenrolled patients. Variation in Institutional Review Board decisions is common; however, it is difficult to understand the privacy or ethical concerns raised by analysis of deidentified screening data for clinical trials. Unfortunately, this Institutional Review Board practice serves only to increase the difficulty in answering research questions about enrollment disparities in a valid manner. Finally, we were unable to explore the cause of heterogeneity in enrollment and distribution of race by center because we did not have details about the participating study centers. This is an important area of future research because characterizing and exporting the center level factors that explain greater fractions of study enrollment is one approach to improve research participation in lowenrollment centers.
CONCLUSION
We demonstrated that older patients are underrepresented in clinical trials of ALI. Contrary to our hypotheses, women were not underrepresented and were even more likely to be enrolled than men, whereas racial/ethnic minorities were equally represented compared with white patients. Ensuring age, sex, and racial/ ethnic diversity in clinical trials improves the power of subgroup analysis in highrisk patients, establishes equity in access to the benefits of and in the distribution of burden from clinical research, and most importantly, reduces threats to a trial's external validity. With each passing year, the typical critically ill patient becomes older and has a greater number of comorbidities. As a result, the need for studies testing therapies in older patients has never been greater and will only increase.
